<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129463">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944176</url>
  </required_header>
  <id_info>
    <org_study_id>Si323/2013</org_study_id>
    <nct_id>NCT01944176</nct_id>
  </id_info>
  <brief_title>The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients</brief_title>
  <official_title>The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokines in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Airway inflammation is partly driven by Th17 and Th17-polarizing cytokines that is
      steroid-resistant. Statins could suppress IL-17 cytokines in other diseases such as
      atherosclerosis and multiple sclerosis in mouse model. The investigators hypothesize that
      statins might provide anti-inflammatory benefit of suppressing IL-17 cytokines in COPD
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sputum neutrophils</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum cytokines</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1-6-12</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin, placebo</intervention_name>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Bestatin</other_name>
    <other_name>B1-6-12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable COPD without an exacerbation within 3 months prior to study entry

          -  mild, moderate and severe COPD with or without treatments, regardless of COPD
             medications

        Exclusion Criteria:

          -  Concomitant other chronic lung diseases including with TB and malignancy

          -  HIV

          -  Being on immunosuppressive drugs and systemic corticosteroids

          -  Dyslipidemic patients with recent cardiovascular or cerebrovascular disease within 6
             month prior to study entry

          -  Cognitive impairment

          -  Currently on macrolides, azole anti-fungal agents, amiodarone and amlodipine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kittipong Maneechotesuwan, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine Siriraj Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kittipong Maneechotesuwan, MD., PhD.</last_name>
    <phone>024197757</phone>
    <email>kittipong.man@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok-noi</city>
        <state>BKK</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kittipong Maneechotesuwan, MD., PhD</last_name>
      <phone>024197757</phone>
      <email>sikmn@mahidol.ac.th</email>
    </contact>
    <investigator>
      <last_name>Kittipong Maneechotesuwan, MD., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Kittipong Maneechotesuwan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Statins</keyword>
  <keyword>Cytokines</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
